A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study).
Shigeru TanzawaSunao UshijimaKazuhiko ShibataTakuo ShibayamaAkihiro BesshoKyoichi KairaToshihiro MisumiKenshiro ShiraishiNoriyuki MatsutaniHisashi TanakaMegumi InabaTerunobu HaruyamaJunya NakamuraTakayuki KishikawaMasanao NakashimaKeiichi IwasaKeiichi FujiwaraTadashi KohyamaShoichi KuyamaNaoki MiyazawaTomomi NakamuraHiroshi MiyawakiHiroo IshidaNaohiro OdaNobuhisa IshikawaRyotaro MorinagaKei KusakaNobukazu FujimotoToshihide YokoyamaKenichi GembaTakeshi TsudaHideyuki NakagawaHirotaka OnoTetsuo ShimizuMorio NakamuraSojiro KusumotoRyuji HayashiHiroki ShirasakiNobuaki OchiKeisuke AoeNobuhiro KanajiKosuke KashiwabaraHiroshi InoueNobuhiko SekiPublished in: Therapeutic advances in medical oncology (2021)
Japan Registry of Clinical Trials, jRCTs031190127, registered 1 November 2019, https://jrct.niph.go.jp/latest-detail/jRCTs031190127.